ABSTRACT Glutathione is translocated out of cells; cells that have membrane-bound y-glutamyl transpeptidase can utilize translocated glutathione, whereas glutathione exported from cells that do not have appreciable transpeptidase enters the blood plasma. Glutathione is removed from the plasma by the kidney and other organs that have transpeptidase. Studies in which mice and rats were treated with buthionine sulfoximine, a selective and potent inhibitor of 'y-glutamylcysteine synthetase and therefore of glutathione synthesis, show that glutathione turns over at a significant rate in many tissues, especially kidney, liver, and pancreas; the rate of turnover in mouse skeletal muscle is about 60% of that in the kidney. Experiments on rats surgically deprived of one or both kidneys and treated with the y-glutamyl transpeptidase inhibitor D-y-glutamyl-o-carboxy)phenylhydrazide establish that extrarenal -y-glutamyl transpeptidase activity accounts for the utilization of about one-third of the total blood plasma glutathione. Normal animals treated with the transpeptidase inhibitor excrete large amounts of glutathione in their urine. They also excrete 'y-glutamylcysteine, suggesting that cleavage of glutathione at the cysteinylglycine bond may be of metabolic significance. The present and earlier findings lead to a tentative scheme (presented here) for the metabolism and translocation of glutathione, y-glutamyl amino acids, and related compounds.
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Studies in which selective inhibitors of the enzymes of the y-glutamyl cycle were used to probe mammalian GSH metabolism, and related investigations, show that the cycle functions in vivo (1) (2) (3) (4) . Thus, intracellular GSH is a substrate for -y-glutamyl transpeptidase, an enzyme located on the external surface of certain cells such as renal cells. Direct studies show that GSH is translocated across cell membranes as a discrete step in the 'y-glutamyl cycle (5, 6) . Cells that lack appreciable transpeptidase activity (e.g., liver cells) also translocate GSH; GSH translocated from such cells is carried by the blood plasma to the kidney and other tissues that have substantial amounts of transpeptidase. y-Glutamyl amino acids, which may be formed from GSH and extracellular amino acids by transpeptidation, are translocated into renal and probably other cells.
We have now examined new facets of GSH metabolism and its translocation between organs by studies in which mice were treated with DL-buthionine-SR-sulfoximine (BSO), a potent selective inhibitor of y-glutamylcysteine synthetase and therefore of GSH synthesis (7, 8) . The findings indicate that GSH turns over at a significant rate in virtually all mammalian tissues. Studies on rats surgically deprived of one or both kidneys and treated with the y-glutamyl transpeptidase inhibitor D-'y-glutamyl-(o-carboxy)phenylhydrazide (5) establish that there is a significant amount of extrarenal transpeptidase.
L-a-amino[14C]butyrate (5) , BSO (8) , and D-y-glutamyl-(ocarboxy)phenylhydrazide (5) were prepared as described. Male mice (NCS strain) were obtained from The Rockefeller University. Male rats were obtained from Taconic Farms (Germantown, NY) and Camm Research (Wayne, NJ).
Methods. Total glutathione, referred to as GSH in this paper, was determined with GSH reductase and 5,5'-dithiobis(2-nitrobenzoate) essentially as described (9) . Animals were killed by decapitation and exsanguination. The excised tissues were homogenized in 5 ml of 1% picric acid per g of tissue, and the homogenates were centrifuged to yield protein-free supernatants, aliquots (1) (2) (3) (4) (5) ,tl) of which were assayed for GSH. Several tissues (liver, brain, heart, lung, spleen, and skeletal muscle) were also frozen in a mixture of dry ice and ethanol before analysis; no change in the tissue GSH level resulted from this procedure. Freezing of the other tissues led to a marked decrease in GSH content. During exsanguination, blood was collected into a beaker containing 5 ,mol of NaEDTA; after immediate centrifugation, the plasma was quickly mixed with 0.5 vol of 10% sulfosalicylic acid. After centrifugation, the supernatant was assayed for GSH. D-'y-Glutamyl-(o-carboxy)phenylhydrazide (5) (11, 12) . Brain GSH also turns over slowly (13) . Analyses of the brain revealed that BSO is transported into the brain; the concentration attained, however, is relatively low.
Abbreviation: BSO, DL-buthionine-SR-sulfoximine. 5606
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Proc. Natl. Acad. Sci. USA 76 (1979) 5607 After a single dose of BSO, the GSH levels in the liver and kidney of mice decreased rapidly and smoothly to about 15-20% of the control values and then increased toward control levels (Fig. 1) . The more rapid return of the GSH content of the liver may reflect an increased rate of enzyme resynthesis in the liver or, possibly, an increased capacity of the liver to metabolize the inhibitor.
Experiments on nephrectomized rats (Table 3) showed that there is substantial extrarenal transpeptidase, which accounts for about one-third of the total GSH utilized. The baseline plasma GSH levels were [17] [18] ,uM (Exps. 1 (20) 0.87 ± 0.05 (19) 0.35 ± 0.10 (21) Rats (90-100 g) were fed ad lib and were injected with 200 mM BSO as indicated. When the compound was administered subcutaneously (sc), it was given as a single injection on the back; when the compound was administered intraperitoneally (ip), one-half the dose was given initially and the remainder was given 1.5 hr later. Analyses showed that the tissue concentrations of BSO were higher at 2 hr than at 4 hr, indicating substantial clearance of the compound by 4 hr. Values in parentheses are percentage of control value.
Biochemistry: Griffith (Fig. 2 IA and IIA) .
DISCUSSION
The GSH level of many tissues decreases soon after administration of BSO. Assuming that GSH synthesis is completely inhibited and that utilization proceeds at its normal rate, the rate of GSH disappearance reflects the rate of GSH turnover. The highest turnover rate was found in the kidney, followed by liver, pancreas, and skeletal muscle. Because muscle accounts for about 40% of the total body weight of mice, the decrease of total muscle GSH after administration of BSO amounts to -'1.6 ,umol/hr. This is appreciable compared to kidney (; '2.7 ymol/hr), liver (;4.5 ,umol/hr), and pancreas (-0.1 ,tmol/hr).
In the rat the rate of turnover of muscle GSH is relatively less but still is substantial. The decline of liver and kidney GSH levels was smooth rather than biphasic, providing no evidence for separate pools of GSH that turn over at different rates. Assuming that the decrease in tissue GSH after administration of BSO is due to translocation of GSH to the blood plasma, it may be calculated that the total GSH translocated is much larger than the observed accumulation of GSH in the plasma when bilaterally nephrectomized animals are given the transpeptidase inhibitor. At [1] y-Glutamylcysteine (or its disulfide), like other y-glutamyl amino acids, may be transported into renal cells.
The data (Table 3) indicate that there is considerable extrarenal transpeptidase, which accounts for about one-third of the total plasma GSH utilized; the remainder is cleared by the kidney. The mechanisms by which the kidney clears plasma GSH include glomerular filtration followed by utilization by transpeptidase. That GSH may also be cleared by other pathways is suggested by the finding of y-glutamylcysteine in the urine of mice treated with inhibitors of transpeptidase (5) and also by the observation that perfused kidneys clear an amount of GSH in excess of that filtered (14) . Pathways that need to be further explored include the uptake of intact GSH and GSH metabolism initiated by reaction 1. Previously, Hahn et al. (15) found that GSH given intravenously to rats is rapidly cleared from the plasma and that clamping of the renal arteries decreased GSH utilization. These workers concluded that GSH degradation occurs mainly in the kidney, but they also obtained evidence consistent with extrarenal degradation of GSH.
A tentative scheme that integrates findings now available about GSH metabolism and translocation is given in Fig. 3 . GSH is synthesized intracellularly (steps 6 and 7) and translocated through the cell membrane (step 10) where it may be oxidized (16, 17) ; both GSH and GSSG are substrates of transpeptidase (step 1); GSH is more active than the latter in transpeptidation (17) . Transpeptidase and dipeptidase activities (step 2) lead to formation of y-glutamyl amino acids, glutamate, glycine, cysteine, cystine, cysteinylglycine, cysteinyl-bisglycine, and mixed disulfides between GSH, cysteine, and cysteinylglycine. There appear to be transport mechanisms for the free amino acids, and possibly for cysteinylglycine, which can be split by intracellular dipeptidase (step 8). There is direct evidence (2, *) for transport into the kidney of intact y-glutamylamino acids (step 11), which may be substrates of 'y-glutamylcyclotransferase (step 4). The quantitativeaspects of these reactions, which occur also in extrarenal tissues [e.g., ciliary body, choroid plexus (18, 19) , and intestine (20) ], need to be considered in relation to the specificity of cyclotransferase (21) and to the apparently relatively low activity of 5-oxoprolinase (step 5) in some tissues. GSH participates in other reactions (not shown in Fig. 3 ) (22), including conversion of GSH to GSSG by transhydrogenases and glutathione peroxidase, conversion of GSSG to GSH by GSH reductase, and reactions involved in mercapturic acid formation. Mercapturic acid formation appears to involve steps analogous to those shown in Fig. 3-i. e., translocation of GSH derivatives formed by GSH S-transferases followed by extracellular cleavage of the glutamate and glycine moieties and translocation of the corresponding substituted cysteine molecules into the cell for acetylation.
Translocation of intracellular GSH appears to be a general property of many, and perhaps all, cells. The in vvo studies carried out with inhibitors of transpeptidase and GSH synthesis have demonstrated the generality of this phenomenon (5, 6) and have thus resolved the initially puzzling observations that GSH is located predominantly intracellularly and that a major fraction of the transpeptidase is localized on the external surface of cells. Previously, evidence was found for export of GSSG from erythrocytes (23) and perfused liver (24) in the presence of strong oxidants. Results of recent studies on efflux of GSH from isolated perfused liver preparations (25) , lymphoid cells (6) , and fibroblasts (26) are consistent with the conclusion drawn from the studies with selective enzyme inhibitors: that translocation of GSH is a general cellular phenomenon. Transloca 
